Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
109.64
+1.14 (1.05%)
Jun 16, 2025, 4:00 PM - Market closed
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $897.84M in the quarter ending March 31, 2025, a decrease of -0.46%. This brings the company's revenue in the last twelve months to $4.06B, up 5.76% year-over-year. In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth.
Revenue (ttm)
$4.06B
Revenue Growth
+5.76%
P/S Ratio
1.66
Revenue / Employee
$1,451,717
Employees
2,800
Market Cap
6.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
JAZZ News
- 6 days ago - Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer - PRNewsWire
- 7 days ago - Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PRNewsWire
- 14 days ago - Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - PRNewsWire
- 14 days ago - Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - PRNewsWire
- 18 days ago - Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PRNewsWire
- 26 days ago - Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - PRNewsWire
- 27 days ago - Jazz Pharmaceuticals: One Step Forward, One Back - Seeking Alpha
- 5 weeks ago - Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript - Seeking Alpha